Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for KL1333 in Mitochondrial disease, primary mitochondrial myopathies. The expected timing is based on the latest available company guidance and may change.
07/30/26:- FALCON enrollment completion in 2026 reiterated; late-2027 readout unchanged.
Verification
Confirm timing and program details against the company announcement or filing.